Healthcare entity
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Dr. Christian Behrenbruch, the most common co-covered peer. The tracked stories average 2 original sources each. William Blair & Company, L.L.C. appears in 1 tracked Healthcare story from August 20, 2026.
Last mentioned: 3d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Dr. Christian Behrenbruch, the most common co-covered peer. The tracked stories average 2 original sources each. William Blair & Company, L.L.C. appears in 1 tracked Healthcare story from August 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 12 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering William Blair & Company, L.L.C.. Shared-story counts are live from our verified record — not editorial picks.
H1 2026 results announced
Telix released its half-year results, reporting US$68 million invested in therapeutics R&D and highlighting late-stage program ProstACT Global.
ATM facility established
Telix entered into an equity distribution agreement with Morgan Stanley & Co. LLC and William Blair & Company, L.L.C. to establish an at-the-market equity facility for ADS issuance at prevailing market prices.
H1 2026 reporting period ended
Telix's half-year financial reporting period closed for the six months ended June 30, 2026.
For healthcare and health IT leaders, Telix's half-year update is a supply-chain signal: the company is expanding radiopharmaceutical manufacturing across four countries to support precision medicine demand. The US$68 million therapeutics R&D investment and TMS expansion point to more reliable access to short-lived isotopes.
William Blair & Company, L.L.C. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
